Lymphocytes. 2. Differentiation. Differentiation of lymphoid precursor cells.

Jánossy, G.; Pizzolo, Giovanni

doi:10.1136/jcp.s3-13.1.48

Cited by 7 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All considerations given above do not prove the mainstream in immune oncology. Though the bone marrow (BM) is the only primary source of lymphocytes in nude mice, they possess prothymocytes, and 3% -6% of splenocytes are Thy-1-positive, [92]. The viability of both normal and malignant tissues in immunodeficient mice depends rather on the number of HSC and immature descendants of the lymphoid-myeloid axis, like CD 133, CD34 CD31, CD90, Thy-1, and TdT-positive cells.…”

Section: Discussionmentioning

confidence: 99%

Time for a New Paradigm in Oncology? Viewpoint of the Radiobiologist

Shoutko

2024

OJBIPHY

View full text Add to dashboard Cite

The current immunooncology artificially ignores the connection with lymphopoiesis, though is only its derivative. Hematopoietic stem cells (HSC) provide physiological regeneration of biomass of the host, fetus, and malignant tumors, as well, as the cells' reparation after sub-lethally injuring in any tissues and their renewal. HSC, especially of lymphoid lineage, are the most vulnerable of those, which are responsible for viability of organism. Natural and artificial deficits of HSC determine aging, multi-organs syndromes and death of the host, because their current proliferative resource (CPR) is individually limited at birth, and is spending irreversibly during wounds' healing, pregnancy, tumor growth, and on. CPR, being an integral value of the number of stem cells along the length of their telomeres, is a "shagreen skin", for which the tumor competes with normal tissues as a quasi-embryonic favorite and winner, especially in the final period of a shortening the life. The primary approach to cancer treatment must prioritize the preservation of CPR remnants, rather than their destruction, in order to temporarily halt the malignant process. The re-targeting of HSC from tumors in favor of normal tissues is the immediate objective of competitive therapy, which allows for preserving the rest of the CPR host's resources, especially in patients with advanced cancer. However, the contradictory and insignificant practically, the dogma of antitumor cellular immunity continues to dominate and hinder progress in oncology.

show abstract

Section: Discussionmentioning

confidence: 99%

Time for a New Paradigm in Oncology? Viewpoint of the Radiobiologist

Shoutko

2024

OJBIPHY

View full text Add to dashboard Cite

show abstract

Differential diagnosis of malignant lymphoma and nonlymphoid tumors using monoclonal anti-leucocyte antibody

Pizzolo

Sloane

Beverley

et al. 1980

Cancer

107

View full text Add to dashboard Cite

Pathologic samples from 34 cases of human solid malignancies were tested for reactivity with monoclonal anti-human leucocyte antibody, designated 2D1. This antibody detects a human leucocyte antigen (HLe-I) that is expressed strongly on B and T lymphoid cells and weakly on early hemopoietic cells, but is not found on normal mesenchymal and epithelial tissues. This study demonstrates the use of this reagent in cryostat sections of tumor samples using indirect immunofluorescence in combination with other lymphoid markers such as anti-T cell serum, anti-Ia-like serum (detecting p28, 33 "B cell associated" membrane antigen) and antisera to different immunoglobulin isotypes. Tumor cells from all 12 cases of epithelial malignancies and sarcomas were HLe-I- although adjacent (normal) lymphoid cells showed strong positive staining. In contrast, 20 cases of lymphoma (B- as well as T-cell types) were HLe-I+. Two other malignancies involving the lymphoid system were HLe-I- and failed to express any of the other lymphoid markers tested.

show abstract

The Reticulo-Epithelial (Re) Cellular Network of the Mammalian Thymus

Immunological Aspects of Neoplasia — The Role of the Thymus

View full text Add to dashboard Cite

Lymphocytes. 2. Differentiation. Differentiation of lymphoid precursor cells.

Cited by 7 publications

References 53 publications

Time for a New Paradigm in Oncology? Viewpoint of the Radiobiologist

Time for a New Paradigm in Oncology? Viewpoint of the Radiobiologist

Differential diagnosis of malignant lymphoma and nonlymphoid tumors using monoclonal anti-leucocyte antibody

The Reticulo-Epithelial (Re) Cellular Network of the Mammalian Thymus

Contact Info

Product

Resources

About